Physician profile
Frederick A Burton
NPI 1912947326
$12,790.88
in general payments reported to CMS, 2019-2025
51 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,695 · 2020: $1,516 · 2021: $2,268 · 2022: $1,356 · 2023: $2,074 · 2024: $817 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,022.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,690.79 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $1,261.36 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $949.36 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $901.69 | 2019-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $704.57 | 2019-2025 | Viberzi, Linzess |
| Amgen INC. | $576.84 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.05 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $419.89 | 2019-2025 | Mounjaro |
| Allergan, INC. | $379.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $303.77 | 2021-2023 | |
| Dexcom, INC. | $254.46 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $253.84 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $223.29 | 2019-2023 | |
| Amarin Pharma, INC. | $180.88 | 2019-2022 |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.